OncoMed Pharmaceuticals, Inc.
) were positively impacted with the company presenting
encouraging data on its oncology candidates, demcizumab and
OMP-59R5, at the 2014 Gastrointestinal Cancers Symposium.
Initial data on demcizumab from an ongoing phase Ib study
revealed that the candidate in combination with
) Abraxane and
Eli Lilly and Company
) Gemzar (gemcitabine) was well tolerated as a first-line therapy
in patients suffering from stage IV pancreatic cancer. Data also
revealed that 50% of patients treated with the above combination
showed partial responses, according to the response evaluation
criteria in solid tumors (RECIST). Moreover, around 33% of
patients had stable disease with an 83% clinical benefit
Encouraged by the impressive results, OncoMed, which went
public only in July last year, intends to evaluate the candidate
as a first-line therapy in the advanced pancreatic cancer
indication in the latter half of 2014. We note that demcizumab is
part of OncoMed's oncology deal with Celgene inked late last
year. The deal pertains to the joint development and
commercialization of up to six anti-cancer stem cell candidates
from OncoMed's biologics pipeline.
OncoMed also presented encouraging initial data from the phase
Ib portion of its ongoing ALPINE (Antibody therapy in first-Line
Pancreatic cancer Investigating anti-Notch Efficacy and safety)
study on another of its pipeline candidate OMP-59R5. The study is
also evaluating OMP-59R5 in combination with Gemzar and Abraxane
as a first-line therapy in patients with advanced pancreatic
cancer. OncoMed intends to evaluate the candidate in a phase II
portion of the ALPINE study in the second quarter of 2014.
We believe investor focus will remain on updates pertaining to
OncoMed, a biopharmaceutical company, carries a Zacks Rank #2
(Buy). A better-ranked stock in the biopharma space includes
) which carries a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
CELGENE CORP (CELG): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
ONCOMED PHARMA (OMED): Free Stock Analysis
To read this article on Zacks.com click here.